TroVax

TroVax is a cancer vaccine developed by Oxford BioMedica, a biopharmaceutical company specializing in the development of gene-based therapies. The vaccine is designed to stimulate the immune system to destroy cancer cells expressing the 5T4 antigen, a protein present in many types of cancer.

History[edit | edit source]

TroVax was first developed in the early 2000s by Oxford BioMedica. The vaccine has undergone several clinical trials, including a Phase III trial for renal cell carcinoma (RCC), a type of kidney cancer. However, the trial did not meet its primary endpoint of improving overall survival, leading to a halt in its development.

Mechanism of Action[edit | edit source]

TroVax works by stimulating the body's immune system to target and destroy cancer cells expressing the 5T4 antigen. The vaccine contains a modified virus that carries the gene for the 5T4 antigen. When administered, the immune system recognizes the 5T4 antigen as foreign, triggering an immune response.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to evaluate the safety and efficacy of TroVax. These trials have involved patients with various types of cancer, including renal cell carcinoma, prostate cancer, and colorectal cancer. While some trials have shown promising results, others have not met their primary endpoints.

Future Development[edit | edit source]

Despite the setback in the Phase III trial for renal cell carcinoma, Oxford BioMedica continues to explore the potential of TroVax in other types of cancer. The company is also investigating the possibility of combining TroVax with other therapies to enhance its effectiveness.